(22) previously identified three gene expression subgroups within KRAS-mutated adenocarcinomas, and reported that these subgroups were independently associated with co-mutation genomic alterations in KRAS and the tumor suppressor genes TP53, STK11, or CDKN2A. In our study, patients with such co-mutations demonstrated similar treatment effects in PFS and tumor size changes relative to the ITT population (Figure S3). The gene discussed is KRAS; the disease is neoplasm.